Industry leaders from Samsung Biologics and Fujifilm Biotechnologies discuss how regional manufacturing, dual sourcing and networked CDMO capacity are reshaping pharma supply chains

It’s no secret that pharmaceutical companies today are rethinking global supply networks. As the industry faces global disruptions and trade friction, supply chain resiliency and security are top of mind. Recent supply chain disruptions have shown how localized crises, regulatory bottlenecks or political instability can upend concentrated production and expose downstream markets to drug shortages. As a result, the geography of drug manufacturing has become central to national security discussions, accelerating efforts to build domestic capacity and trusted regional supply corridors..... [ContractPharma]